Adverum Biotechnologies, Inc. (ADVM) News

Adverum Biotechnologies, Inc. (ADVM)

Today's Latest Price: $14.21 USD

0.24 (1.72%)

Updated Nov 24 4:00pm

Add ADVM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter ADVM News Items

ADVM News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ADVM News From Around the Web

Below are the latest news stories about Adverum Biotechnologies Inc that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Assessing Adverum

Procrastination is my sin. It brings me naught but sorrow. I know that I should stop it. In fact, I will--tomorrow”― Gloria Pitzer Today, we look at a name that made me some significant profits earlier this year. However, the stock has fallen on some hard times, and I have...

Bret Jensen on Seeking Alpha | September 29, 2020

Adverum Bio raises $189M via public offering

Adverum Biotechnologies (ADVM) has priced its public offering of 14.5M common shares at $13.00/share, for expected gross proceeds of ~$188.5M.Underwriters' overallotment is an additional 2,175,000 shares.Closing date is August 17.Shares are down 6% premarket. See how ADVM has performed against similar stocks.Previously: Adverum readies $200M equity offering (Aug. 11)...

Seeking Alpha | August 13, 2020

Equillium Jumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma

Equillium stock jumps on encouraging Itolizumab interim data Equillium Inc. (EQ) reported positive interim data for its lead drug candidate Itolizumab from the first two cohorts of the Phase 1b trial. The drug candidate was found to be generally well-tolerated and five out of seven patients demonstrated a complete response...

Avisol Capital Partners on Seeking Alpha | August 12, 2020

Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting…

GlobeNewswire | August 12, 2020

Adverum's gene therapy shows encouraging activity in early-stage eye disorder study

Adverum Biotechnologies ([[ADVM]] -9.8%) has announced positive new interim data from Cohorts 1-4 of the OPTIC Phase 1 trial of ADVM-022 intravitreal injection gene therapy in patients with wet age-related macular degeneration, who require frequent anti-VEGF injections.Data showed treatment response from both high and low doses of ADVM-022, and demonstrated long-term...

Seeking Alpha | August 11, 2020

Adverum Biotechnologies, Inc. (ADVM) CEO Laurent Fischer on Q2 2020 Results - Earnings Call Transcript

Adverum Biotechnologies, Inc. (ADVM) Q2 2020 Results Conference Call August 10, 2020 4:30 PM ET Company Participants Myesha Lacy - Investor Relations & Corporate Communications Laurent Fischer - Chief Executive Officer Arshad Khanani - MD and Director of Clinical Research of Sierra Eye Associates Aaron Osborne - Chief Medical Officer...

SA Transcripts on Seeking Alpha | August 11, 2020

Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results

-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero…

GlobeNewswire | August 10, 2020

Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update

REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting…

GlobeNewswire | July 29, 2020

Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy

REDWOOD CITY, Calif., July 21, 2020 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare.

Yahoo | July 21, 2020

Did Hedge Funds Make The Right Call On Adverum Biotechnologies, Inc. (ADVM) ?

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 20, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5992 seconds.